Trusted News Discovery Since 2008
{{/content}}
USFDA issues warning letter to Intas over 'quality lapses'
Credit: IndiaTimes- Published on December 4, 2023
US FDA issues warning letter to Intas for violations at Ahmedabad facility, citing lapses in CGMP regulations. The letter highlights identity, strength, quality, and purity issues in the company's drugs. It mentions that Intas' QA and production departments failed to ensure data reliability. The USFDA also found that operators...
You are here
Related news from verified sources
US health regulator issues warning letter to Intas Pharmaceuticals CEO and MD Nimish Chudgar for manufacturing lapses and violation of CGMP regulations at the...
on December 10, 2023 • IndiaTimes